Stallergenes SA, Research and Pharmaceutical Development, 6 rue Alexis de Tocqueville, 92160 Antony, France.
Expert Rev Vaccines. 2014 Dec;13(12):1463-73. doi: 10.1586/14760584.2014.948861. Epub 2014 Sep 4.
Allergen-specific immunotherapy is used to treat patients exposed and co-sensitized to the two common house dust mites, Dermatophagoides pteronyssinus and Dermatophagoides farinae. Based on seroepidemiological studies and a detailed characterization of mite allergens, an optimal immunotherapeutic product should associate extracts from the two Dermatophagoides species, and include both bodies and fecal particles. Both subcutaneous and sublingual immunotherapies performed with aqueous mite extracts are safe and efficacious in children and adults with mite-induced rhinitis and/or asthma. Double-blind placebo-controlled studies are conducted to further document the efficacy of immunotherapeutic products, with promising results that were obtained already with sublingual tablets. Current developments of second-generation products relying upon recombinant allergens and peptides are reviewed.
变应原特异性免疫疗法用于治疗同时暴露于和共致敏于两种常见屋尘螨，屋尘螨和粉尘螨的患者。基于血清流行病学研究和对螨变应原的详细特征描述，一种理想的免疫治疗产品应该联合来自两种屋尘螨的提取物，且应包含螨体和粪粒。使用螨水提取物进行皮下和舌下免疫疗法，对于尘螨诱导的鼻炎和/或哮喘的儿童和成人来说是安全且有效的。进行双盲安慰剂对照研究以进一步记录免疫治疗产品的疗效，已经获得了舌下片剂的有前景的结果。本文综述了基于重组变应原和肽的第二代产品的最新进展。
